UA118368C2 - METHOD OF DETERMINING AR-THERAPY RESISTANCE - Google Patents

METHOD OF DETERMINING AR-THERAPY RESISTANCE

Info

Publication number
UA118368C2
UA118368C2 UAA201609005A UAA201609005A UA118368C2 UA 118368 C2 UA118368 C2 UA 118368C2 UA A201609005 A UAA201609005 A UA A201609005A UA A201609005 A UAA201609005 A UA A201609005A UA 118368 C2 UA118368 C2 UA 118368C2
Authority
UA
Ukraine
Prior art keywords
androgen receptor
determining
therapy resistance
relates
modified
Prior art date
Application number
UAA201609005A
Other languages
Ukrainian (uk)
Inventor
Джеймс Девід Джозеф
Джеффрі Х. Хеджер
Джон Лі Сенсінтаффар
Нхін Лу
Цзін Циань
Ніколас Д. Сміт
Original Assignee
Арагон Фармасьютікалз, Інк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Арагон Фармасьютікалз, Інк. filed Critical Арагон Фармасьютікалз, Інк.
Publication of UA118368C2 publication Critical patent/UA118368C2/en

Links

Landscapes

  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Винахід стосується способу застосування модифікованого поліпептиду андрогенного рецептора, в тому числі й способу застосування модифікованого поліпептиду андрогенного рецептора як агента скринінгу для ідентифікації та розробки модуляторів андрогенного рецептора третього покоління. А також, стосується способу застосування таких модуляторів андрогенного рецептора для лікування ракових захворювань, а саме раку передміхурової залози.The invention relates to a method of using a modified androgen receptor polypeptide, including a method of using a modified androgen receptor polypeptide as a screening agent for the identification and development of third-generation androgen receptor modulators. It also relates to a method of using such androgen receptor modulators for the treatment of cancer, namely prostate cancer.

UAA201609005A 2012-07-27 2013-07-26 METHOD OF DETERMINING AR-THERAPY RESISTANCE UA118368C2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261676842P 2012-07-27 2012-07-27
US201361783763P 2013-03-14 2013-03-14
US201361829123P 2013-05-30 2013-05-30
UA201501717 2013-07-26

Publications (1)

Publication Number Publication Date
UA118368C2 true UA118368C2 (en) 2019-01-10

Family

ID=65577206

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201609005A UA118368C2 (en) 2012-07-27 2013-07-26 METHOD OF DETERMINING AR-THERAPY RESISTANCE

Country Status (1)

Country Link
UA (1) UA118368C2 (en)

Similar Documents

Publication Publication Date Title
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
IL282077B (en) Macropinocytosing human anti-cd46 antibodies and targeted cancer therapeutics
CY1119590T1 (en) DLL3 REGULATORS AND METHODS OF USE
GEP20217331B (en) Anti-tigit antibodies
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
PH12014502601A1 (en) ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
MX2016002826A (en) Anti-b7-h1 antibodies for treating tumors.
MX2014009751A (en) Antibodies to integrin avvb6 and use of same to treat cancer.
EA201491530A1 (en) MODULATORS OF ESTROGEN RECEPTORS AND THEIR APPLICATION
EA201591750A1 (en) ANTIBODIES AGAINST B7-H4 AND IMMUNOCONJUGATES
MX2016001963A (en) Screening method.
CY1123716T1 (en) ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC, EUNAUCH-RESISTANT PROSTATE CANCER
SG2014008304A (en) C10rf32 antibodies, and uses thereof for treatment of cancer
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
IN2014DN05885A (en)
PT4095130T (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
DK2825558T3 (en) Combination therapy for the treatment of ovarian cancer
IN2014KN02993A (en)
MX2014012843A (en) Anti-pdgf-c antibodies.
BR112013023154A2 (en) imaging apparatus, imaging method and imaging program
DK3317300T3 (en) BISPECIFIC ANTIBODIES FOR USE IN CANCER HOUR THERAPY
EA201591304A1 (en) APPLICATION OF THE COMPLEX, ENABLING CHROMATIN TRANSCRIPTION (FACT), WITH CANCER
UA118368C2 (en) METHOD OF DETERMINING AR-THERAPY RESISTANCE
SG11201404312VA (en) Method of synthesizing peptides, proteins and bioconjugates